Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
First Claim
1. A method for treating a B-cell-related malignancy disease in a human comprising administering to said human either(i) a conjugated anti-CD74 antibody or an antigen-binding fragment thereofandan unconjugated anti-CD20 antibody or an antigen-binding fragment thereof,wherein said conjugated anti-CD74 antibody or antigen-binding fragment thereof and said unconjugated anti-CD20 antibody or antigen-binding fragment thereof are administered concurrently or sequentiallyor(ii) a conjugated anti-CD20 antibody or an antigen-binding fragment thereofandan unconjugated anti-CD74 antibody, or an antigen-binding fragment thereof,wherein said conjugated anti-CD20 antibody or antigen-binding fragment thereof and said unconjugated anti-CD74 antibody or antigen-binding fragment thereof are administered concurrently or sequentially,wherein predosing with a non-radiolabeled antibody is not performed and wherein the unconjugated anti-CD20 or unconjugated anti-CD74 is added as a maintenance therapy to keep proliferating tumor cells from target escape.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.
103 Citations
44 Claims
-
1. A method for treating a B-cell-related malignancy disease in a human comprising administering to said human either
(i) a conjugated anti-CD74 antibody or an antigen-binding fragment thereof and an unconjugated anti-CD20 antibody or an antigen-binding fragment thereof, wherein said conjugated anti-CD74 antibody or antigen-binding fragment thereof and said unconjugated anti-CD20 antibody or antigen-binding fragment thereof are administered concurrently or sequentially or (ii) a conjugated anti-CD20 antibody or an antigen-binding fragment thereof and an unconjugated anti-CD74 antibody, or an antigen-binding fragment thereof, wherein said conjugated anti-CD20 antibody or antigen-binding fragment thereof and said unconjugated anti-CD74 antibody or antigen-binding fragment thereof are administered concurrently or sequentially, wherein predosing with a non-radiolabeled antibody is not performed and wherein the unconjugated anti-CD20 or unconjugated anti-CD74 is added as a maintenance therapy to keep proliferating tumor cells from target escape.
-
4. A method for treating a B-cell related malignancy disease in a human comprising administering to said human a bispecific antibody that binds to both CD74 and CD20, said bispecific antibody comprising either:
-
(i) a conjugated anti-CD74 antibody or antigen-binding fragment thereof and an unconjugated anti-CD20 antibody or antigen binding fragment thereof, or (ii) a conjugated anti-CD20 antibody or antigen-binding fragment thereof and an unconjugated anti-CD74 antibody or antigen-binding fragment thereof, wherein the unconjugated anti-CD20 or anti-CD74 is a maintenance therapy to keep proliferating tumor cells from target escape.
-
-
38. A method for treating a B-cell related malignancy disease comprising administering to a human a therapeutic composition comprising:
-
(a) a pharmaceutically acceptable vehicle containing unconjugated anti-CD20 antibody, or an antigen-binding fragment thereof, or unconjugated single chain antibody fusion protein, said antibody fusion protein comprising a recombinantly produced antigen-binding molecule in which two or more of the same or different single-chain antibodies, or two or more of the same or different antigen-binding fragments are linked, wherein said unconjugated antibody or antigen-binding fragment thereof or said unconjugated fusion protein targets CD20, and said fusion protein or antigen-binding fragment comprises the variable domains, or the CDRs of the heavy and light chains of said CD20 antibody; and (b) a pharmaceutically acceptable vehicle containing a conjugated humanized monoclonal antibody or antigen-binding fragment thereof that binds CD74, said antibody or antigen-binding fragment thereof being conjugated to doxorubicin wherein (a) and (b) are administered concurrently or sequentially. - View Dependent Claims (39, 42, 43, 44)
-
Specification